Hot
重组抗人CD16单抗(3G8) | Syd Labs PA007277.m1
体内实验级重组抗人CD16单克隆抗体(克隆号3G8)，小鼠IgG1 Kappa(克隆号：3G8，Syd Labs货号：PA007277.m1)，适用于体外和体内研究，纯度>95%。其不变区为小鼠Mouse IgG1 Kappa，样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007277.m1 |
|---|---|
| 产品名称 | 重组抗人CD16单抗(3G8) | Syd Labs PA007277.m1 |
| 英文名 | In Vivo Grade Recombinant Anti-human CD16 Monoclonal Antibody（Clone 3G8）,Mouse IgG1 Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 分化簇16，Fc-γ-rIIIA 和 Fc-γ-rIIIB（cluster of differentiation 16, Fc gamma RIIIA and Fc gamma RIIIB） |
| 概述 | Syd Labs提供重组小鼠 IgG1同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定（Recombinant mouse IgG1 isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator）。 |
| 克隆号 | 3G8 |
| 同种型 | Mouse IgG1 Kappa |
| 免疫源 | 抗人 CD16单克隆抗体(克隆号: 3G8)是在哺乳动物细胞中产生的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质。提供特级体内实验级重组抗人CD16单克隆抗体(克隆号3G8)，小鼠IgG1 Kappa（In Vivo Grade Recombinant Anti-human CD16 Monoclonal Antibody（Clone 3G8）,Mouse IgG1 Kappa)。 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD16单克隆抗体(克隆号3G8)，小鼠IgG1 Kappa（In Vivo Grade Recombinant Anti-human CD16 Monoclonal Antibody（Clone 3G8）,Mouse IgG1 Kappa)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存3个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007277.m1 Syd Labs提供重组小鼠 IgG1同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定（Recombinant mouse IgG1 isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator）。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人 CD16蛋白影响的生物学途径的测定。 |
文献
PA007277.m1: Syd Labs 抗人CD16单克隆抗体(克隆号3G8) ，体内实验级重组，小鼠IgG1 Kappa（In vivo Grade Recombinant Anti-human CD16 Monoclonal Antibody (Clone: 3G8), Mouse IgG1 Kappa）
重组3G8抗体能够结合人及非人灵长类动物的CD16（即FcγRIII）。CD16是一种表达于自然杀伤（NK）细胞、中性粒细胞、单核细胞、巨噬细胞及特定T细胞表面的分化群分子，由Fc受体FcγRIIIa (CD16a)和FcγRIIIb (CD16b)组成。作为触发NK细胞介导溶菌作用研究最深入的膜受体，CD16属于免疫球蛋白超家族（IgSF），并参与抗体依赖性细胞毒性作用（ADCC）。利用针对CD16的抗体，可通过荧光激活细胞分选术（FACS）或磁珠激活细胞分选术来分离特定的免疫细胞群体。
抗人CD16单抗(3G8)部分引用文献:
1. Human blood neutrophils generate ROS through FcγR-signaling to mediate protection against febrile P. falciparum malaria.
Ofori, E. A., et al. Commun Biol. 2023 Jul;6(1):743. PMID: 37463969
“Before incubating with merozoites, cells were treated with antibodies against FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16), as described previously in ref. 10. Cells were treated for 30 min. at 37 °C with 10 µg/ml of anti-human CD64; anti-human CD32; anti-human CD16, or a combination of these to block FcγR-I, II, and III, respectively. …Blood phagocytes, such as neutrophils and monocytes, generate reactive oxygen species (ROS) as a part of host defense response against infections. …Plasmodium falciparum merozoites opsonized with naturally occurring IgG triggered both intracellular and extracellular ROS generation in blood phagocytes, with neutrophils being the main contributors. …Using specific inhibitors, we show that both FcγRIIIB and FcγRIIA acted synergistically to induce ROS production in neutrophils, and that NADPH oxidase 2 and the PI3K intracellular signal transduction pathway were involved in this process. …Here, we used peripheral blood leukocytes (PBLs) to study ROS production intracellularly and extracellularly using freshly purified P. falciparum merozoites and naturally occurring antibodies from samples from well-established longitudinal cohort studies (LCS) performed in Ghana and India.”
Ofori, E. A., et al. Commun Biol. 2023 Jul;6(1):743. PMID: 37463969
“Before incubating with merozoites, cells were treated with antibodies against FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16), as described previously in ref. 10. Cells were treated for 30 min. at 37 °C with 10 µg/ml of anti-human CD64; anti-human CD32; anti-human CD16, or a combination of these to block FcγR-I, II, and III, respectively. …Blood phagocytes, such as neutrophils and monocytes, generate reactive oxygen species (ROS) as a part of host defense response against infections. …Plasmodium falciparum merozoites opsonized with naturally occurring IgG triggered both intracellular and extracellular ROS generation in blood phagocytes, with neutrophils being the main contributors. …Using specific inhibitors, we show that both FcγRIIIB and FcγRIIA acted synergistically to induce ROS production in neutrophils, and that NADPH oxidase 2 and the PI3K intracellular signal transduction pathway were involved in this process. …Here, we used peripheral blood leukocytes (PBLs) to study ROS production intracellularly and extracellularly using freshly purified P. falciparum merozoites and naturally occurring antibodies from samples from well-established longitudinal cohort studies (LCS) performed in Ghana and India.”
2. Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection.
Mu, S., et al. Front Med (Lausanne). 2022 Oct;9. PMID: 36341247
“As SARS-CoV-2 strains continue to evolve, new variants have been increasing in the current global pandemic. …Here, we constructed a series of SARS-CoV-2 variants, including engineered double-mutant variants containing an RBD mutation and D614G in the spike protein and natural epidemic variants, and tested whether plasma samples and top neutralizing antibodies in our laboratory from convalescent patients mediated the ADE effects of these SARS-CoV-2 variants. …Currently, neutralizing antibody and vaccine strategies have been developed by targeting the SARS-CoV-2 strain identified during the early phase of the pandemic. …Only one antibody, 55A8, from the same batch of convalescent patients mediated the ADE effects of multiple SARS-CoV-2 variants in vitro, including six double-mutant variants and four epidemic variants, suggesting that ADE activities may be closely related to the antibody itself and the SARS-CoV-2 variants’ S proteins. …These data suggested that potential neutralizing antibodies may need to undergo ADE screening tests for SARS-CoV-2 variants, which should aid in the future design of effective antibody-based therapies.”
Mu, S., et al. Front Med (Lausanne). 2022 Oct;9. PMID: 36341247
“As SARS-CoV-2 strains continue to evolve, new variants have been increasing in the current global pandemic. …Here, we constructed a series of SARS-CoV-2 variants, including engineered double-mutant variants containing an RBD mutation and D614G in the spike protein and natural epidemic variants, and tested whether plasma samples and top neutralizing antibodies in our laboratory from convalescent patients mediated the ADE effects of these SARS-CoV-2 variants. …Currently, neutralizing antibody and vaccine strategies have been developed by targeting the SARS-CoV-2 strain identified during the early phase of the pandemic. …Only one antibody, 55A8, from the same batch of convalescent patients mediated the ADE effects of multiple SARS-CoV-2 variants in vitro, including six double-mutant variants and four epidemic variants, suggesting that ADE activities may be closely related to the antibody itself and the SARS-CoV-2 variants’ S proteins. …These data suggested that potential neutralizing antibodies may need to undergo ADE screening tests for SARS-CoV-2 variants, which should aid in the future design of effective antibody-based therapies.”